Showing results (171-180 of 258) with videos related to
Sort By:
Pageof 26
Journal of Lipid Research|September 5, 2021
HSP90 inhibitors reduce cholesterol storage in Niemann-Pick type C1 mutant fibroblastsNina H Pipalia, Syed Z Saad, Kanagaraj Subramanian, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeuticsW Marston Linehan, Peter A Pinto, Ramaprasad Srinivasan, et al.The Journal of Biological Chemistry|March 20, 2009
Inhibition of tumor cell motility by the interferon-inducible GTPase MxAJ Frederic Mushinski, Phuongmai Nguyen, Lisa M Stevens, et al.Cell Chemical Biology|February 2, 2022
Selective vulnerabilities in the proteostasis network of castration-resistant prostate cancerArielle Shkedi, Isabelle R Taylor, Frank Echtenkamp, et al.Molecular Cell|October 17, 2008
Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37Cara K Vaughan, Mehdi Mollapour, Jennifer R Smith, et al.Journal of Immunology (Baltimore, Md. : 1950)|December 22, 2007
Ex vivo rapamycin generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejectionJacopo Mariotti, Jason Foley, Unsu Jung, et al.Cancer Biology & Therapy|August 19, 2008
Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancerXu-Hui Zhang, Mahadev Rao, Joseph A Loprieato, et al.Journal of Medicinal Chemistry|June 29, 2018
Exploration of Benzothiazole Rhodacyanines as Allosteric Inhibitors of Protein-Protein Interactions with Heat Shock Protein 70 (Hsp70)Hao Shao, Xiaokai Li, Michael A Moses, et al.Cancer Cell|August 16, 2005
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stabilityJennifer S Isaacs, Yun Jin Jung, David R Mole, et al.Journal of Clinical Pharmacology|December 5, 2015
UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulationCody J Peer, Andrew K L Goey, Tristan M Sissung, et al.Pageof 26